1. Introduction {#sec1}
===============

The concept that the nutritional properties of food cannot be recapitulated by, and go substantially beyond, its profile of essential macronutrients (proteins, sugars, and lipids) and micronutrients (vitamins and minerals) is now firmly entrenched in both human and animal nutrition \[[@B1]\]. It explains various once puzzling observations, from the difference between the pharmacological profile of alcohol and wine \[[@B2]\] to the higher susceptibility to parasite infection associated with the nutrition of bees with sugar solutions rather than with honey \[[@B3]\]. Within the differences between alcohol and red wine, one of the most remarkable ones regards the effect on blood pressure \[[@B2], [@B4]\]. While the regular consumption of alcohol elevates blood pressure of approximately 1 mm Hg for each 10 g of alcohol consumed \[[@B2], [@B4]\], red wine, at least when associated with moderate drinking (1--4 standard drinks a day), can substantially reverse alcohol-related hypertension and have a beneficial effect on hypertension and overall cardiac morbidity \[[@B2]\]. This effect has been associated with the phenolic constituents of wine, mostly procyanidins (GSPs) \[[@B5]\], and two preliminary intervention studies on prehypertensive patients have supported the view that GSPs lower blood pressure \[[@B6], [@B7]\]. The mechanist details of this activity have been worked out. Thus, procyanidins directly inhibit angiotensin-converting enzyme (ACE) \[[@B8]\] and indirectly increase the lifetime of endothelially generated nitrogen oxide by inhibiting the production of superoxide, its major physiological scavenger, from endothelial NADP oxidase \[[@B9]\]. The overall result of a decreased peripheral resistance is a reduction of both systolic and diastolic blood pressures, with potential beneficial effects for all risk factors associated with hypertension (stroke, heart disease, congestive heart failure, and kidney disease).

Conventionally, high blood pressure is associated with values of systolic and diastolic pressure higher than 139 mm Hg and 89 mm Hg, respectively, while the corresponding normal values are considered those \<120 mm Hg and \<80 mm Hg \[[@B10]\]. The grey area between normality and hypertension has been named prehypertension and is generally treated only with diet and lifestyle modifications (self-monitoring, exercise, and relaxation), as often happens for the stage 1 of hypertension, the one associated with 140--159/90--95 mm Hg values \[[@B10]\]. Severe hypertension is an important risk factor for coronary artery disease, more important than high non-HDL cholesterol or obesity \[[@B11]\], but there is mounting evidence that also chronic prehypertension is detrimental for cardiovascular health. Nevertheless, the side-effect profile of hypotensive drugs (diuretics, beta-blockers, and ACE-inhibitors) makes their generalized use in prehypertensive patients questionable \[[@B10]\], providing a rationale to investigate the potential of supplementation with diet-derived agents to promote the attainment of healthy values of blood pressure in this population. In this context, GSPs are the best validated dietary constituents, due to their occurrence in red wine, where contents in the range of 1 g/L are not uncommon, and their identification as the molecular link between wine and its protective cardiovascular properties \[[@B5]\].

GSP is an umbrella name that covers a wide range of products, differing for their contents of monomeric catechins and their degree of oligomerization and decoration with galloyl moieties \[[@B12]\]. GSPs are type B procyanidins, characterized by a single interflavane bond, and represent the best investigated class of condensed tannins \[[@B13]\]. Only the lower homologues (2--5 units) have been shown to be absorbed, either directly or after microbial metabolization. Although the extent of absorption is controversial \[[@B14]\], mass balance experiments with radiolabeled procyanidin B2, a dimeric condensed tannin, have shown an overall significant (\>60%) systemic label absorption \[[@B15]\]. For these reasons, we have selected a standardized GSPE (Enovita) enriched in lower oligomers for this study.

2. Material and Methods {#sec2}
=======================

Enovita, a standardized grape seed extract, and the corresponding blank formulation were provided by Indena (Milan, Italy). Enovita contains ca. 8.6% (HPLC) monomeric procyanidins (catechin, epicatechin, and epicatechin gallate) and ca. 91% OPC (GPC), of which 9% (HPLC) are of the dimeric type. The water content is ca. 5%.

Inclusion criteria for this study were a general good health and borderline hypertension, defined as prehypertension (120--139 mm Hg/80--89 mm Hg) and stage 1 hypertension (140--159 mm Hg/90--99 mm Hg) \[[@B10]\]. The evaluation of general good health involved clinical evaluation and history, full blood test panel to rule out alterations in the lipid profile, fasting glucose or hepatitis markers, an overall normal hematocrit, and proteins profile and coagulation, as well as exclusion of hormonal alterations (thyroid and adrenal).

The nondrug intervention included diet (reduction of salt, alcohol, and caffeinated drinks) and lifestyle (regular exercise, improvement of sleep time, relaxation, and reduction of smoke). No other nutritional elements, vitamins, or drugs were used in the observation period. The same management plan was assigned to all subjects, who were then divided into three groups:group 1---300 mg Enovita/day + management plan;group 2---150 mg Enovita/day + management plan;group 3: controls---management plan only.

Group 1 was made of 37 subjects (14 females), group 2 of 35 subjects (18 females), and group 3 of 47 subjects (19 females) ([Table 1](#tab1){ref-type="table"}). The age range for volunteers was 45--55 years, and the mean age was 51.33 ± 5.31 years in group 1, 49.90 ± 5.31 in group 2, and 49.40 ± 3.00 in group 3. Also, the average BMI was fairly similar within the three groups, namely, 25.41 ± 0.80 Kg/m^2^ in the high dosage group (group 1), 25.20 ± 0.73 Kg/m^2^ in the low dosage group (group 2), and 25.11 ± 0.70 Kg/m^2^ in the control group (group 3) ([Table 1](#tab1){ref-type="table"}). No side effects were reported during the execution of the study, and formulation tolerability (both for Enovita and the corresponding blank formulation) was very good. Based on the number of used capsules, compliance was \>94% in group 1 and \>95% in group 2. Blood pressure and heart rate were measured digitally. LDF measurements were taken after 30 minutes of supine rest and acclimatization at 21°C for additional 30 minutes. A linear probe (Vasamedics Laserflo, St. Paul, USA) was used for all measurements, taken on the dorsum of foot, and expressed in flux unit \[[@B16]\]. In hypertensive subjects, flux is generally decreased due to vasoconstriction and is increased by treatment, exercise, and control of the risk factors associated with lifestyle.

All measured target parameters ([Table 1](#tab1){ref-type="table"}) have a nonnormal, skewed, or unknown distribution. Therefore, the ANOVA (with the Bonferroni correction) was used to evaluate the before-after results and the Mann-Whitney *U* test for the evaluation of statistically significant differences. A numerosity of at least 20 comparable subjects per group (treatment versus control) was considered necessary to overcome the possible, unavoidable even under the best experimental conditions, differences due to the variability of the microcirculatory target measurements, particularly the laser Doppler test.

3. Results and Discussion {#sec3}
=========================

GSPs are endowed with high antioxidant activity, orders of magnitude higher than vitamin C, and have been extensively investigated for their capacity to interfere with the development of the cardiovascular disease (CVD) phenotype associated with the oxidation of membrane lipids (endothelial dysfunction, formation of oxidized LDL, and activation of phagocytic cells) \[[@B13]\]. Epidemiological evidence related to the so-called French paradox suggests that GSPs can substantially buffer a high income of animal fats in the diet, although evidence for this activity is controversial because of the difficulty of recapitulating a complex dietary lifestyle in a controlled clinical experiment \[[@B5]\]. On the other hand, there is growing evidence that GSPs can also address another important element of the CVD phenotype, namely, hypertension, and two controlled studies have suggested that the preclinical observations on procyanidins and blood pressure have indeed a clinical translation \[[@B6], [@B7]\]. These studies were carried out in subjects with avert metabolic syndrome and were of short duration (four weeks). We have now investigated the activity of GSPs in a controlled and longer registry study (four months) on mildly hypertensive but otherwise healthy and only slightly overweight subjects, complementing the observation on blood pressure with a series of other parameters of relevance for the predisease status of the population in study that included heart rate, ECG analysis, and measurements of the microcirculatory status by LDF.

The borderline hypertensive subjects (119) were sorted out in three groups, similar in terms of age and all the objective parameters evaluated, namely, systolic and diastolic blood pressures, microcirculatory status (LDF), heart rate, and plasma oxidative status ([Table 2](#tab2){ref-type="table"}). Group 1 (37 subjects) and group 2 (35 subjects) complemented the management plan with Enovita at two different daily dosages (300 mg/day for group 1 and 150 mg/day for group 2), while in subjects from group 3 (47), only the management plan was implemented and served as the control. The endpoints of the study were evaluated monthly, that is, at weeks 4, 8, and 12, in order to assess the kinetics of development of any beneficial effect.

A decrease of systolic blood pressure was observed in all four groups of the study at month 1, but the decrease was significantly higher in the treatment group (*P* \< 0.05). Thus, the average drop of systolic pressure was 28 mm Hg in the high dosage branch and 21 mm Hg in the lower dosage group, while in their respective control groups the decrease was more modest (11 mm Hg). During the next checks, the systolic pressure underwent a further, but much lower, decrease to eventually reach, at the end of the study, an average value of 112 mm Hg in the high dosage group, 123 mm Hg in the lower dosage group, and 141 mm Hg in the control group. In this latter group, no significant further decrease in systolic pressure was observed after the first check. The decrease was, as expected, lower for the diastolic pressure, but a difference between the treatment and the control could still be observed. Thus, in the two treatment groups, a decrease of the diastolic pressure was also observed and developed more gradually in time, eventually reaching 82.3  ±  3.0 mm Hg (from 91.3  ±  2.0 mm Hg) for group 1 and 85.3  ±  2.0 mm Hg (from 91.3 mm Hg) for group 2 ([Table 2](#tab2){ref-type="table"}). Conversely, the decrease was marginal in the control group (from 90.4  ±  2.5 mm Hg to 88.9  ±  3.2 mm Hg). As expected from the data on blood pressure, heart rate was also significantly better reduced in the interventional arms compared to their controls ([Table 1](#tab1){ref-type="table"}), decreasing from 78  ±  3.5 mm Hg to 70  ±  1.5 mm Hg in group 1, from 77  ±  3.4 mm Hg to 72  ±  2.0 mm Hg in group 2, and from 77.2  ±  3.3 mm Hg to 73.2  ±  2.2 mm Hg in the control (group 3).

GSPs have been reported to improve endothelial function and promote microcirculation \[[@B16]\], decreasing the plasma oxidative status \[[@B17]\], and both activities were confirmed in our study ([Table 1](#tab1){ref-type="table"}).

Taken together, our data suggest that GSPs, at least in the profile associated with Enovita, are worth considering to complement dietary and lifestyle changes associated with the attainment of a healthy blood pressure status. The data on blood pressure complement the beneficial activity of GSPs on the CVD phenotype associated with the oxidation of membrane lipids (endothelial dysfunction, formation of oxidized LDL, and activation of phagocytic cells) \[[@B17]\], suggesting that this class of condensed tannins, at least as fractions enriched in lower oligomers, is worth systematic studies for cardiovascular prevention in subjects at risk, providing, for borderline patients, a nondrug option that is better accepted than mainstream medication.

###### 

Key parameters at inclusion, 4, 8, 12, and 16 weeks.

  Time        Systolic pressure   Diastolic pressure   Laser Doppler flux   Heart rate       Plasma-free radicals                                                                                                                                  
  ----------- ------------------- -------------------- -------------------- ---------------- ---------------------- ----------- ----------------- --------------- ------------ ----------- ------------- ----------- -------------- -------------- -----------
  Inclusion   149; 4.5            150; 3               153.3; 4.4           91; 3.2          91.3; 2                90.4; 2.5   1.1; 0.01         1.1; 0.2        1.1; 0.01    78; 3.5     77.3; 4       77.2; 3.3   378; 22        382; 21        383; 23
  4 weeks     121.3; 5.4^∗\#^     129; 2.2^∗\#^        142.3; 5\*           86.3; 3.9\*      88; 2\*                88.4; 3\*   1.28; 0.01^∗\#^   1.2; 0.1        1.16; 0.01   73; 2.2\*   73; 3.2\*     74; 3.2\*   ---            ---            ---
  8 weeks     119; 4.9^∗\#^       125; 3^∗\#^          142; 3.9             84.4; 2.8^∗\#^   86.1; 2.1\*            87; 3.6     2.13; 0.1^∗\#^    1.6; 0.2^∗\#^   1.22; 0.1    71; 3.1\*   73; 2.1       74; 3.1     324; 19^∗\#^   339; 32^∗\#^   376; 29\*
  12 weeks    113; 3.3^∗\#^       122; 3.2^∗\#^        139; 3.5             83; 3.3^\#^      86.3; 2^\#^            88; 2.2     2.22; 0.2^∗\#^    1.9; 0.2^∗\#^   1.3; 0.1     69; 2.3\*   72.2; 2^\#^   74; 2.3     ---            ---            ---
  16 weeks    112; 3.5^∗\#^       123; 2.1^∗\#^        141; 4.3             82.3; 3^\#^      85.3; 2^\#^            88.9; 3.2   2.23; 0.1^\#^     1.9; 0.2^\#^    1.2; 0.1     70; 1.5     72; 2.3       73.2; 2.2   317; 22^∗\#^   342; 28^\#^    374; 22

\*(*P* \< 0.05) indicates statistical variations in comparison with previous value.

\#: better than controls.

###### 

Subjects details.

  Treatment                  Number of subjects completing the study   Age           Compliance   Tolerability   Dropouts
  -------------------------- ----------------------------------------- ------------- ------------ -------------- ----------
  150 mg + best management   37 (14 females)                           51.33; 5.31   94%          Very good      0
  300 mg + best management   35 (18 females)                           49.9; 5.2     95%          Very good      0
  Best management            47 (19 females)                           49.4; 3       95%          Very good      3
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